ERBB2 and neoplasm: Higher expression of EDI3 (224826_at) was observed in HER2 + tumours compared to HER2 − tumours in the combined analysis of all datasets (P < 0.001, Mann–Whitney U test), as well as in four datasets when analysed separately.